Although Wee1 has been previously reported to be an oncogenic factor [19–22], and suppressing Wee1 exerted an anticancer effect in ovarian cancer [35] and osteosarcoma cells [36], whereas in CML, on the other hand, Wee1’s engagement related with DRR has never been extensively illustrated. The gene discussed is WEE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.